Imaging nicotine- and amphetamine-induced dopamine release in rhesus monkeys with [11C]PHNO vs [11C]raclopride PET

Neuropsychopharmacology

Volumn 39, Issue 4, 2014, Pages 866-874

  Gallezot, Jean Dominique ^a   Kloczynski, Tracy ^a   Weinzimmer, David ^a   Labaree, David ^a   Zheng, Ming Qiang ^a   Lim, Keunpoong ^a   Rabiner, Eugenii A ^b   Ridler, Khanum ^b   Pittman, Brian ^a   Huang, Yiyun ^a   Carson, Richard E ^a   Morris, Evan D ^a   Cosgrove, Kelly P ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

11C PHNO; amphetamine; dopamine; nicotine; non human primate; PET

Indexed keywords

AMPHETAMINE; ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; FEMALE; MACACA MULATTA; MAGNETIC RESONANCE IMAGING; NICOTINE; NICOTINIC AGONISTS; OXAZINES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RACLOPRIDE;

EID: 84894059171     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.286     Document Type: Article

References (53)

1. Barrett SP, Boileau I, Okker J, Pihl RO, Dagher A (2004). The hedonic response to cigarette smoking is proportional to dopamine release in the human striatum as measured by positron emission tomography and [11C]raclopride. Synapse 54: 65-71.
2. Brazell MP, Mitchell SN, Joseph MH, Gray JA (1990). Acute administration of nicotine increases the in vivo extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid and ascorbic acid preferentially in the nucleus accumbens of the rat: comparison with caudate-putamen. Neuropharmacology 29: 1177-1185.
3. Brody AL, London ED, Olmstead RE, Allen-Martinez Z, Shulenberger S, Costello MR et al (2010). Smoking-induced change in intrasynaptic dopamine concentration: effect of treatment for tobacco dependence. Psychiatry Res 183: 218-224.
4. Brody AL, Mandelkern MA, Olmstead RE, Allen-Martinez Z, Scheibal D, Abrams AL et al (2009a). Ventral striatal dopamine release in response to smoking a regular vs a denicotinized cigarette. Neuropsychopharmacology 34: 282-289.
5. Brody AL, Mandelkern MA, Olmstead RE, Scheibal D, Hahn E, Shiraga S et al (2006). Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens. Arch Gen Psychiatry 63: 808-816.
6. Brody AL, Olmstead RE, Abrams AL, Costello MR, Khan A, Kozman D et al (2009b). Effect of a history of major depressive disorder on smoking-induced dopamine release. Biol Psychiatry 66: 898-901.
7. Brody AL, Olmstead RE, London ED, Farahi J, Meyer JH, Grossman P et al (2004). Smoking-induced ventral striatum dopamine release. Am J Psychiatry 161: 1211-1218.
8. Brown DJLuthra SKBrady FPrenant CDijkstra DWikstrom H (eds) (1997). Labelling of the D2-agonist-(+)-PHNO using [11C]- propionyl chloride. Proceedings of the XIIth International Symposium on Radiopharmaceutical Chemistry. John Wiley and Sons: Uppsala, Sweden.
9. CDC (2010). Vital signs: current cigarette smoking among adults aged 4/18 years-United States, 2005-2010. Morb Mortal Wkly Rep 60: 1207-1212.
10. Cumming P, Rosa-Neto P, Watanabe H, Smith D, Bender D, Clarke PB et al (2003). Effects of acute nicotine on hemodynamics and binding of [11C]raclopride to dopamine D2,3 receptors in pig brain. Neuroimage 19: 1127-1136.
11. Dewey SL, Brodie JD, Gerasimov M, Horan B, Gardner EL, Ashby CR Jr (1999). A pharmacologic strategy for the treatment of nicotine addiction. Synapse 31: 76-86.
12. Di Chiara G, Imperato A (1988). Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85: 5274-5278.
13. Domino EF, Tsukada H (2009). Nicotine sensitization of monkey striatal dopamine release. Eur J Pharmacol 607: 91-95.
14. Fuchs H, Nagel J, Hauber W (2005). Effects of physiological and pharmacological stimuli on dopamine release in the rat globus pallidus. Neurochem Int 47: 474-481.
15. Gallezot JD, Beaver JD, Gunn RN, Nabulsi N, Weinzimmer D, Singhal T et al (2012). Affinity and selectivity of [(11) C]-(+)- PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo. Synapse 66: 489-500.
16. Gerasimov MR, Franceschi M, Volkow ND, Rice O, Schiffer WK, Dewey SL (2000). Synergistic interactions between nicotine and cocaine or methylphenidate depend on the dose of dopamine transporter inhibitor. Synapse 38: 432-437.
17. Ginovart N, Galineau L, Willeit M, Mizrahi R, Bloomfield PM, Seeman P et al (2006). Binding characteristics and sensitivity to endogenous dopamine of [11C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography. J Neurochem 97: 1089-1103.
18. Ginovart N, Willeit M, Rusjan P, Graff A, Bloomfield PM, Houle S et al (2007a). Positron emission tomography quantification of [11C]-(+)-PHNO binding in the human brain. J Cereb Blood Flow Metab 27: 857-871.
19. Ginovart N, Willeit M, Rusjan P, Graff A, Bloomfield PM, Houle S et al (2007b). Positron emission tomography quantification of [11C]-(+)-PHNO binding in the human brain. J Cereb Blood Flow Metab 27: 857-871.
20. Girgis RR, Xu X, Miyake N, Easwaramoorthy B, Gunn RN, Rabiner EA et al (2011). In vivo binding of antipsychotics to D(3) and D(2) receptors: a PET study in baboons with [(11)C]-(+)- PHNO. Neuropsychopharmacology 36: 887-895.
21. Gunn RN, Gunn SR, Turkheimer FE, Aston JAD, Cunningham VJ (2002). Positron emission tomography compartmental models: a basis pursuit strategy for kinetic modeling. J Cereb Blood Flow Metab 22: 1425-1439.
22. Hauber W, Fuchs H (2000). Dopamine release in the rat globus pallidus characterised by in vivo microdialysis. Behav Brain Res 111: 39-44.
23. Hwang DR, Kegeles LS, Laruelle M (2000). (-)-N-[(11)C] propylnorapomorphine: a positron-labeled dopamine agonist for PET imaging of D(2) receptors. Nucl Med Biol 27: 533-539.
24. Ichise M, Ballinger JR, Golan H, Vines D, Luong A, Tsai S et al (1996). Noninvasive quantification of dopamine D2 receptors with iodine-123-IBF SPECT. J Nucl Med 37: 513-520.
25. Ichise M, Cohen RM, Carson RE (2008). Noninvasive estimation of normalized distribution volume: application to the muscarinic-2 ligand [(18)F]FP-TZTP. J Cereb Blood Flow Metab 28: 420-430.
26. Ichise M, Toyama H, Innis RB, Carson RE (2002). Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metab 22: 1271-1281.
27. Imperato A, Mulas A, DiChiara G (1986). Nicotine preferentially stimulates dopamine release n the limbic system of freely moving rats. Eur J Pharmacol 132: 337-338.
28. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN et al (2007). Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27: 1533-1539.
29. Lammertsma AA, Hume SP (1996). Simplified reference tissue model for PET receptor studies. NeuroImage 4(Part 1): 153-158.
30. Laruelle M (2000). Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20: 423-451.
31. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL (1996). Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16: 834-840.
32. Logan J, Fowler JS, Volkow ND, Wolf A, Dewey SL, Schlyer D et al (1990). Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)- cocaine PET studies in human subjects. J Cereb Blood Flow Metab 10: 740-747.
33. Marenco S, Carson RE, Berman KF, Herscovitch P, Weinberger DR (2004). Nicotine-induced dopamine release in primates measured with [11C]raclopride PET. Neuropsychopharmacology 29: 259-268.
34. Marshall DL, Redfern PH, Wonnacott S (1997). Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: comparison of naive and chronic nicotine-treated rats. J Neurochem 68: 1511-1519.
35. Mizrahi R, Houle S, Vitcu I, Ng A, Wilson AA (2010). Side effects profile in humans of (11)C-(+)-PHNO, a dopamine D(2/3) agonist ligand for PET. J Nucl Med 51: 496-497.
36. Montgomery AJ, Lingford-Hughes AR, Egerton A, Nutt DJ, Grasby PM (2007). The effect of nicotine on striatal dopamine release in man: a [11C]raclopride PET study. Synapse 61: 637-645.
37. Morris E, Kim S, Sullivan J, Wang S, Normandin M, Constantinescu C et al (2013). Creating dynamic images of short-lived dopamine fluctuations with lp-ntPET: dopamine movies of cigarette smoking. JoVE. doi:10.3791/50358.
38. Narendran R, Slifstein M, Guillin O, Hwang Y, Hwang DR, Scher E et al (2006). Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo. Synapse 60: 485-495.
39. Paxinos G, Huang X, Toga A (2000). The Rhesus Monkey Brain in Stereotaxic Coordinates. Academic Press: San Diego, CA.
40. Sandiego CM, Weinzimmer D, Carson RE (2013). Optimization of PET-MR registrations for nonhuman primates using mutual information measures: a Multi-Transform Method (MTM). NeuroImage 64: 571-581.
41. Scott DJ, Domino EF, Heitzeg MM, Koeppe RA, Ni L, Guthrie S et al (2007). Smoking modulation of mu-opioid and dopamine D2 receptor-mediated neurotransmission in humans. Neuropsychopharmacology 32: 450-457.
42. Shim I, Javaid JI, Wirtshafter D, Jang SY, Shin KH, Lee HJ et al (2001). Nicotine-induced behavioral sensitization is associated with extracellular dopamine release and expression of c-Fos in the striatum and nucleus accumbens of the rat. Behav Brain Res 121: 137-147.
43. Shotbolt P, Tziortzi AC, Searle GE, Colasanti A, van der Aart J, Abanades S et al (2012).Within-subject comparison of [(11)C]-(+)- PHNO and [(11)C]raclopride sensitivity to acute amphetamine challenge in healthy humans. J Cereb Blood Flow Metab 32: 127-136.
44. Slifstein M, Kegeles LS, Xu X, Thompson JL, Urban N, Castrillon J et al (2010). Striatal and extrastriatal dopamine release measured with PET and [(18)F] fallypride. Synapse 64: 350-362.
45. Sullivan J, Kim S, Cosgrove K, Morris E (2013). Limitations of SRTM, logan graphical method, and equilibrium analysis for measuring transient dopamine release with [11C]raclopride PET. Am J Nucl Med Mol Imag 3: 247-260.
46. Takahashi H, Fujimura Y, Hayashi M, Takano H, Kato M, Okubo Y et al (2007). Enhanced dopamine release by nicotine in cigarette smokers: a double-blind, randomized, placebo-controlled pilot study. Int J Neuropsychopharmacol 11: 1-5.
47. Talhout R, Opperhuizen A, van Amsterdam JG (2007). Role of acetaldehyde in tobacco smoke addiction. Eur Neuropsychopharmacology 17: 627-636.
48. Tsukada H, Miyasato K, Kakiuchi T, Nishiyama S, Harada N, Domino EF (2002). Comparative effects of methamphetamine and nicotine on the striatal [(11)C]raclopride binding in unanesthetized monkeys. Synapse 45: 207-212.
49. Tziortzi AC, Searle GE, Tzimopoulou S, Salinas C, Beaver JD, Jenkinson M et al (2011). Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy. Neuroimage 54: 264-277.
50. Villegier AS, Lotfipour S, McQuown SC, Belluzzi JD, Leslie FM (2007). Tranylcypromine enhancement of nicotine self-administration. Neuropharmacology 52: 1415-1425.
51. Willeit M, Ginovart N, Graff A, Rusjan P, Vitcu I, Houle S et al (2008). First human evidence of d-amphetamine induced displacement of a D2/3 agonist radioligand: a [11C]-(+)-PHNO positron emission tomography study. Neuropsychopharmacology 33: 279-289.
52. Willeit M, Ginovart N, Kapur S, Houle S, Hussey D, Seeman P et al (2006). High-affinity states of human brain dopamine D2/3 receptors imaged by the agonist [11C]-(+)-PHNO. Biol Psychiatry 59: 389-394.
53. Wilson AA, McCormick P, Kapur S, Willeit M, Garcia A, Hussey D et al (2005). Radiosynthesis and evaluation of [11C]-(+)-4- propyl-3,4,4a,5,6,10b- hexahydro-2H-naphtho[1,2-b][1,4]oxazin- 9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J Med Chem 48: 4153-4160.